Gyroscope Therapeutics Announces Initiation of Phase II Programme Evaluating its Investigational Gene Therapy, GT005, for Dry Age-Related Macular Degeneration
LONDON--(BUSINESS WIRE)-- #GeneTherapy--Gyroscope announces initiation of Phase II programme evaluating its investigational gene therapy, GT005, for dry age-related macular degeneration.